Our top pick for
Mobile users
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Akebia Therapeutics stock | 2.6
Own Akebia Therapeutics stock in just a few minutes.
Akebia Therapeutics, Inc is a biotechnology business based in the US. Akebia Therapeutics shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Akebia Therapeutics employs 358 staff and has a trailing 12-month revenue of around USD$340.2 million.
How to buy shares in Akebia Therapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Akebia Therapeutics. Find the stock by name or ticker symbol: AKBA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Akebia Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$2.6, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Akebia Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Akebia Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
How has coronavirus impacted Akebia Therapeutics's share price?
Since the stock market crash in March caused by coronavirus, Akebia Therapeutics's share price has had significant negative movement.
Its last market close was USD$2.6, which is 74.38% down on its pre-crash value of USD$10.15 and 46.35% down on the lowest point reached during the March crash when the shares fell as low as USD$3.805.
If you had bought USD$1,000 worth of Akebia Therapeutics shares at the start of February 2020, those shares would have been worth USD$791.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$330.15.
Akebia Therapeutics share price
Use our graph to track the performance of AKBA stocks over time.Akebia Therapeutics shares at a glance
Information last updated 2020-10-20.
| Latest market close | USD$2.6 |
|---|---|
| 52-week range | USD$2.34 - USD$13.71 |
| 50-day moving average | USD$3.4543 |
| 200-day moving average | USD$9.0134 |
| Wall St. target price | USD$6.86 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.395 |
Buy Akebia Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Akebia Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Akebia Therapeutics price performance over time
Historical closes compared with the close of $2.6 from 2020-11-16
| 1 week (2020-11-23) | -15.31% |
|---|---|
| 1 month (2020-10-30) | 17.12% |
| 3 months (2020-08-28) | -74.71% |
| 6 months (2020-05-29) | -77.66% |
| 1 year (2019-11-29) | -58.66% |
|---|---|
| 2 years (2018-11-30) | -67.82% |
| 3 years (2017-11-30) | -83.29% |
| 5 years (2015-11-30) | -75.77% |
Akebia Therapeutics financials
| Revenue TTM | USD$340.2 million |
|---|---|
| Gross profit TTM | USD$26.5 million |
| Return on assets TTM | -14.83% |
| Return on equity TTM | -86.68% |
| Profit margin | -113.35% |
| Book value | $2.587 |
| Market capitalisation | USD$530.3 million |
TTM: trailing 12 months
Shorting Akebia Therapeutics shares
There are currently 22.2 million Akebia Therapeutics shares held short by investors – that's known as Akebia Therapeutics's "short interest". This figure is 141.8% up from 9.2 million last month.
There are a few different ways that this level of interest in shorting Akebia Therapeutics shares can be evaluated.
Akebia Therapeutics's "short interest ratio" (SIR)
Akebia Therapeutics's "short interest ratio" (SIR) is the quantity of Akebia Therapeutics shares currently shorted divided by the average quantity of Akebia Therapeutics shares traded daily (recently around 12.0 million). Akebia Therapeutics's SIR currently stands at 1.85. In other words for every 100,000 Akebia Therapeutics shares traded daily on the market, roughly 1850 shares are currently held short.
However Akebia Therapeutics's short interest can also be evaluated against the total number of Akebia Therapeutics shares, or, against the total number of tradable Akebia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akebia Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Akebia Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.1781% of the tradable shares (for every 100,000 tradable Akebia Therapeutics shares, roughly 178 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akebia Therapeutics.
Find out more about how you can short Akebia Therapeutics stock.
Akebia Therapeutics share dividends
We're not expecting Akebia Therapeutics to pay a dividend over the next 12 months.
Akebia Therapeutics share price volatility
Over the last 12 months, Akebia Therapeutics's shares have ranged in value from as little as $2.34 up to $13.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Therapeutics's is 1.6459. This would suggest that Akebia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Akebia Therapeutics overview
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
More guides on Finder
-
How to buy Chase Corporation stock
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
-
How to buy CDW Corporation stock | 139.08
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
-
How to buy Camping World stock
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
-
How to buy Catalyst Biosciences stock
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
-
How to buy Bridgeline Digital stock
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
-
How to buy Calavo Growers stock | 72.77
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
-
How to buy Aegion Corporation stock | 15.82
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
-
How to buy Arthur JGallagher-and-Co stock
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
-
How to buy ABB stock
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
-
How to buy Youngevity International stock
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
Ask an Expert